Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2245 to 2253 of 2253 entries
Sorted by: Best Match Show Resources per page
Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　- A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial.

Circulation journal : official journal of the Japanese Circulation Society

Sato N, Uno S, Yamasaki Y, Hirano T, Kim S.
PMID: 34511586
Circ J. 2021 Sep 11; doi: 10.1253/circj.CJ-21-0430. Epub 2021 Sep 11.

BACKGROUND: Tolvaptan is an orally administered aquaretic drug indicated for patients with congestive heart failure (CHF) to remove excess fluid. OPC-61815, a prodrug of tolvaptan with improved water solubility, is considered suitable for intravenous (IV) administration. This Phase II...

Cite
Sato N, Uno S, Yamasaki Y, et al. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　- A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial. Circ J. 2021;doi: 10.1253/circj.CJ-21-0430.
Sato, N., Uno, S., Yamasaki, Y., Hirano, T., Kim, S. (2021). Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　- A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial. Circulation journal : official journal of the Japanese Circulation Society, . https://doi.org/10.1253/circj.CJ-21-0430
Sato, Naoki, et al. "Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　- A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial." Circulation journal : official journal of the Japanese Circulation Society vol. (2021). doi: https://doi.org/10.1253/circj.CJ-21-0430
Sato N, Uno S, Yamasaki Y, Hirano T, Kim S. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure　- A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial. Circ J. 2021 Sep 11; doi: 10.1253/circj.CJ-21-0430. Epub 2021 Sep 11. PMID: 34511586.
Copy Download .nbib Format: NLM
Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies.

Journal of autoimmunity

Arase N, Tsuji H, Takamatsu H, Jin H, Konaka H, Hamaguchi Y, Tonomura K, Kotobuki Y, Ueda-Hayakawa I, Matsuoka S, Hirano T, Yorifuji H, Murota H, Ohmura K, Nakashima R, Sato T, Kumanogoh A, Katayama I, Arase H, Fujimoto M.
PMID: 34896887
J Autoimmun. 2021 Dec 09;126:102774. doi: 10.1016/j.jaut.2021.102774. Epub 2021 Dec 09.

Intracellular proteins are often targeted by autoantibodies in autoimmune diseases; however, the mechanism through which intracellular molecules are targeted remains unknown. We previously found that several intracellular misfolded proteins are transported to the cell surface by HLA class II...

Cite
Arase N, Tsuji H, Takamatsu H, et al. Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. J Autoimmun. 2021;126:102774doi: 10.1016/j.jaut.2021.102774.
Arase, N., Tsuji, H., Takamatsu, H., Jin, H., Konaka, H., Hamaguchi, Y., Tonomura, K., Kotobuki, Y., Ueda-Hayakawa, I., Matsuoka, S., Hirano, T., Yorifuji, H., Murota, H., Ohmura, K., Nakashima, R., Sato, T., Kumanogoh, A., Katayama, I., Arase, H., & Fujimoto, M. (2021). Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. Journal of autoimmunity, 126102774. https://doi.org/10.1016/j.jaut.2021.102774
Arase, Noriko, et al. "Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies." Journal of autoimmunity vol. 126 (2021): 102774. doi: https://doi.org/10.1016/j.jaut.2021.102774
Arase N, Tsuji H, Takamatsu H, Jin H, Konaka H, Hamaguchi Y, Tonomura K, Kotobuki Y, Ueda-Hayakawa I, Matsuoka S, Hirano T, Yorifuji H, Murota H, Ohmura K, Nakashima R, Sato T, Kumanogoh A, Katayama I, Arase H, Fujimoto M. Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. J Autoimmun. 2021 Dec 09;126:102774. doi: 10.1016/j.jaut.2021.102774. Epub 2021 Dec 09. PMID: 34896887.
Copy Download .nbib Format: NLM
Molecular Dynamics Study of Conformational Changes of Tankyrase 2 Binding Subsites upon Ligand Binding.

ACS omega

Hirano Y, Okimoto N, Fujita S, Taiji M.
PMID: 34278146
ACS Omega. 2021 Jun 29;6(27):17609-17620. doi: 10.1021/acsomega.1c02159. eCollection 2021 Jul 13.

The interactions between proteins and ligands are involved in various biological functions. While experimental structures provide key static structural information of ligand-unbound and ligand-bound proteins, dynamic information is often insufficient for understanding the detailed mechanism of protein-ligand binding. Here,...

Cite
Hirano Y, Okimoto N, Fujita S, et al. Molecular Dynamics Study of Conformational Changes of Tankyrase 2 Binding Subsites upon Ligand Binding. ACS Omega. 2021;6(27):17609-17620doi: 10.1021/acsomega.1c02159.
Hirano, Y., Okimoto, N., Fujita, S., & Taiji, M. (2021). Molecular Dynamics Study of Conformational Changes of Tankyrase 2 Binding Subsites upon Ligand Binding. ACS omega, 6(27), 17609-17620. https://doi.org/10.1021/acsomega.1c02159
Hirano, Yoshinori, et al. "Molecular Dynamics Study of Conformational Changes of Tankyrase 2 Binding Subsites upon Ligand Binding." ACS omega vol. 6,27 (2021): 17609-17620. doi: https://doi.org/10.1021/acsomega.1c02159
Hirano Y, Okimoto N, Fujita S, Taiji M. Molecular Dynamics Study of Conformational Changes of Tankyrase 2 Binding Subsites upon Ligand Binding. ACS Omega. 2021 Jun 29;6(27):17609-17620. doi: 10.1021/acsomega.1c02159. eCollection 2021 Jul 13. PMID: 34278146; PMCID: PMC8280666.
Copy Download .nbib Format: NLM
Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan.

Journal of clinical medicine

Kondo M, Noma H, Shimura M, Sugimoto M, Matsui Y, Kato K, Saishin Y, Ohji M, Ishikawa H, Gomi F, Iwata K, Yoshida S, Kusuhara S, Hirai H, Ogata N, Hirano T, Murata T, Tsuboi K, Kamei M, Kinoshita T, Kuwayama S, Hirano Y, Ohta M, Kimura K, Takayama K, Takeuchi M, Takamura Y, Okamoto F, Mitamura Y, Terasaki H, Sakamoto T, Group OBOJCRSJ.
PMID: 34884321
J Clin Med. 2021 Nov 29;10(23). doi: 10.3390/jcm10235619.

PURPOSE: To determine the baseline characteristics of patients with central retinal vein occlusion (CRVO) that were significantly associated with the best-corrected visual acuity (BCVA) at the initial examination.METHODS: This was a retrospective multicenter study using the medical records registered...

Cite
Kondo M, Noma H, Shimura M, et al. Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan. J Clin Med. 2021;10(23)doi: 10.3390/jcm10235619.
Kondo, M., Noma, H., Shimura, M., Sugimoto, M., Matsui, Y., Kato, K., Saishin, Y., Ohji, M., Ishikawa, H., Gomi, F., Iwata, K., Yoshida, S., Kusuhara, S., Hirai, H., Ogata, N., Hirano, T., Murata, T., Tsuboi, K., Kamei, M., Kinoshita, T., Kuwayama, S., Hirano, Y., Ohta, M., Kimura, K., Takayama, K., Takeuchi, M., Takamura, Y., Okamoto, F., Mitamura, Y., Terasaki, H., Sakamoto, T., & Group, O. B. O. J. C. R. S. J. (2021). Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan. Journal of clinical medicine, 10(23), . https://doi.org/10.3390/jcm10235619
Kondo, Mineo, et al. "Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan." Journal of clinical medicine vol. 10,23 (2021). doi: https://doi.org/10.3390/jcm10235619
Kondo M, Noma H, Shimura M, Sugimoto M, Matsui Y, Kato K, Saishin Y, Ohji M, Ishikawa H, Gomi F, Iwata K, Yoshida S, Kusuhara S, Hirai H, Ogata N, Hirano T, Murata T, Tsuboi K, Kamei M, Kinoshita T, Kuwayama S, Hirano Y, Ohta M, Kimura K, Takayama K, Takeuchi M, Takamura Y, Okamoto F, Mitamura Y, Terasaki H, Sakamoto T, Group OBOJCRSJ. Background Factors Affecting Visual Acuity at Initial Visit in Eyes with Central Retinal Vein Occlusion: Multicenter Study in Japan. J Clin Med. 2021 Nov 29;10(23). doi: 10.3390/jcm10235619. PMID: 34884321.
Copy Download .nbib Format: NLM
Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise.

International journal of ophthalmology

Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T.
PMID: 33747814
Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021.

AIM: To evaluate the effectiveness of micropulse laser trabeculoplasty (MLT) for eyes with open angle glaucoma (OAG) under maximal tolerable glaucoma eyedrops and to assess the effect of expertise performing MLT on its clinical effectiveness.METHODS: Medical records of 42...

Cite
Kakihara S, Hirano T, Imai A, et al. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021;14(3):388-392doi: 10.18240/ijo.2021.03.09.
Kakihara, S., Hirano, T., Imai, A., Kurenuma, T., Chiku, Y., & Murata, T. (2021). Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. International journal of ophthalmology, 14(3), 388-392. https://doi.org/10.18240/ijo.2021.03.09
Kakihara, Shinji, et al. "Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise." International journal of ophthalmology vol. 14,3 (2021): 388-392. doi: https://doi.org/10.18240/ijo.2021.03.09
Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021. PMID: 33747814; PMCID: PMC7930551.
Copy Download .nbib Format: NLM
Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Yamada T, Nakanishi Y, Hayashi H, Tanishima S, Mori R, Fujii K, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Matsui A, Tanaka K, Watanabe Y, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S.
PMID: 34903468
HPB (Oxford). 2021 Nov 25; doi: 10.1016/j.hpb.2021.11.008. Epub 2021 Nov 25.

BACKGROUND: Lymph node metastasis (LNM) is one of the most adverse prognostic factors in extrahepatic cholangiocarcinoma (EHCC) cases. As next-generation sequencing technology has become more widely available, the genomic profile of biliary tract carcinoma has been clarified. However, whether...

Cite
Yamada T, Nakanishi Y, Hayashi H, et al. Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB (Oxford). 2021;doi: 10.1016/j.hpb.2021.11.008.
Yamada, T., Nakanishi, Y., Hayashi, H., Tanishima, S., Mori, R., Fujii, K., Okamura, K., Tsuchikawa, T., Nakamura, T., Noji, T., Asano, T., Matsui, A., Tanaka, K., Watanabe, Y., Kurashima, Y., Ebihara, Y., Murakami, S., Shichinohe, T., Mitsuhashi, T., & Hirano, S. (2021). Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association, . https://doi.org/10.1016/j.hpb.2021.11.008
Yamada, Toru, et al. "Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. (2021). doi: https://doi.org/10.1016/j.hpb.2021.11.008
Yamada T, Nakanishi Y, Hayashi H, Tanishima S, Mori R, Fujii K, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Matsui A, Tanaka K, Watanabe Y, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S. Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB (Oxford). 2021 Nov 25; doi: 10.1016/j.hpb.2021.11.008. Epub 2021 Nov 25. PMID: 34903468.
Copy Download .nbib Format: NLM
Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.

Brain tumor pathology

Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I.
PMID: 34826036
Brain Tumor Pathol. 2022 Jan;39(1):14-24. doi: 10.1007/s10014-021-00418-x. Epub 2021 Nov 26.

Since the World Health Organization 2016 classification (2016 WHO), genetic status has been incorporated into the diagnosis of Grade 2/3 gliomas (lower-grade gliomas). Therefore, immunohistochemistry (IHC) of IDH1-R132H, ATRX, and p53 have been used in place of genetic status....

Cite
Nishikawa T, Watanabe R, Kitano Y, et al. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Brain Tumor Pathol. 2021;39(1):14-24doi: 10.1007/s10014-021-00418-x.
Nishikawa, T., Watanabe, R., Kitano, Y., Yamamichi, A., Motomura, K., Ohka, F., Aoki, K., Hirano, M., Kato, A., Yamaguchi, J., Maeda, S., Kibe, Y., Saito, R., Wakabayashi, T., Kato, Y., Sato, S., Ogino, T., Natsume, A., & Ito, I. (2022). Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Brain tumor pathology, 39(1), 14-24. https://doi.org/10.1007/s10014-021-00418-x
Nishikawa, Tomohide, et al. "Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas." Brain tumor pathology vol. 39,1 (2022): 14-24. doi: https://doi.org/10.1007/s10014-021-00418-x
Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Brain Tumor Pathol. 2022 Jan;39(1):14-24. doi: 10.1007/s10014-021-00418-x. Epub 2021 Nov 26. PMID: 34826036.
Copy Download .nbib Format: NLM
The effect of social distancing on the reach of an epidemic in social networks.

Journal of economic interaction and coordination

Gutin G, Hirano T, Hwang SH, Neary PR, Toda AA.
PMID: 33680208
J Econ Interact Coord. 2021 Mar 03;1-19. doi: 10.1007/s11403-021-00322-9. Epub 2021 Mar 03.

How does social distancing affect the reach of an epidemic in social networks? We present Monte Carlo simulation results of a

Cite
Gutin G, Hirano T, Hwang SH, et al. The effect of social distancing on the reach of an epidemic in social networks. J Econ Interact Coord. 2021;1-19doi: 10.1007/s11403-021-00322-9.
Gutin, G., Hirano, T., Hwang, S. H., Neary, P. R., & Toda, A. A. (2021). The effect of social distancing on the reach of an epidemic in social networks. Journal of economic interaction and coordination, 1-19. https://doi.org/10.1007/s11403-021-00322-9
Gutin, Gregory, et al. "The effect of social distancing on the reach of an epidemic in social networks." Journal of economic interaction and coordination vol. (2021): 1-19. doi: https://doi.org/10.1007/s11403-021-00322-9
Gutin G, Hirano T, Hwang SH, Neary PR, Toda AA. The effect of social distancing on the reach of an epidemic in social networks. J Econ Interact Coord. 2021 Mar 03;1-19. doi: 10.1007/s11403-021-00322-9. Epub 2021 Mar 03. PMID: 33680208; PMCID: PMC7925813.
Copy Download .nbib Format: NLM
NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells.

iScience

Shimada R, Koike H, Hirano T, Kato Y, Saga Y.
PMID: 34401671
iScience. 2021 Jul 22;24(8):102890. doi: 10.1016/j.isci.2021.102890. eCollection 2021 Aug 20.

During murine germ cell development, male germ cells enter the mitotically arrested G0 stage, which is an initial step of sexually dimorphic differentiation. The male-specific RNA-binding protein NANOS2 has a key role in suppressing the cell cycle in germ...

Cite
Shimada R, Koike H, Hirano T, et al. NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells. iScience. 2021;24(8):102890doi: 10.1016/j.isci.2021.102890.
Shimada, R., Koike, H., Hirano, T., Kato, Y., & Saga, Y. (2021). NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells. iScience, 24(8), 102890. https://doi.org/10.1016/j.isci.2021.102890
Shimada, Ryuki, et al. "NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells." iScience vol. 24,8 (2021): 102890. doi: https://doi.org/10.1016/j.isci.2021.102890
Shimada R, Koike H, Hirano T, Kato Y, Saga Y. NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells. iScience. 2021 Jul 22;24(8):102890. doi: 10.1016/j.isci.2021.102890. eCollection 2021 Aug 20. PMID: 34401671; PMCID: PMC8350546.
Copy Download .nbib Format: NLM
Showing 2245 to 2253 of 2253 entries